Eisai announces Phase 3 Lenvima combination trial analyses in advanced kidney cancer at ESMO 2026

By Public Technologies
  • Eisai will present final Phase 3 LITESPARK-011 results for advanced kidney cancer at ESMO in Madrid on October 25, 2026.
  • The study supported recent FDA clearance of Welireg with Lenvima for adults with advanced clear-cell kidney cancer previously treated with immunotherapy.
  • LITESPARK-012 findings, also scheduled for October 25, will assess two investigational first-line regimens against Keytruda with Lenvima in advanced clear-cell kidney cancer.
  • An exploratory LEAP-001 biomarker analysis in advanced or recurrent endometrial cancer will be presented October 23, examining treatment response.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eisai Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610150808PR_NEWS_USPR_____NY72423) on October 15, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk